ACRS — Phase 2 Data for Bosakitug in Severe Asthma and CRSwNP
Jun 30, 2025, 5:00:00 AM UTC
Summary
Data from CTTQ’s Phase 2 studies of Bosakitug in severe asthma and chronic rhinosinusitis with nasal polyps expected in the first half of 2025.
Company
ACLARIS THERAPEUTICS INC (ACRS)NASDAQ — Healthcare: Manufacturing, Diagnostics & Research: Pharmaceutical Preparations
www.aclaristx.comSimilar Events
Phase 2 Clinical Trial Top-Line Data Release
Upstream Bio expects to report top-line data from its Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps in the second half of 2025.
clinical readoutPhase 2 Clinical Trial Top-Line Data Release for Severe Asthma
Top-line data from Upstream Bio's ongoing Phase 2 clinical trial in severe asthma is expected in the second half of 2026, furthering the development of verekitug.
clinical readoutStart of Phase 2b Trial in Asthma
The Phase 2b trial for asthma patients is scheduled to begin in Q1 2026 as part of Kymera's ongoing clinical development of KT-621.
clinical readoutBX004 Phase 2b Topline Results Anticipation
Topline results from the Phase 2b study of BX004 are anticipated in Q1 2026, targeting cystic fibrosis treatment.
clinical readout